LON:GNS - Genus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 5,253.33
  • Forecasted Upside: 5.45 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 4,982
▲ +86 (1.76%)

This chart shows the closing price for GNS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNS

Analyst Price Target is GBX 5,253.33
▲ +5.45% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Genus in the last 3 months. The average price target is GBX 5,253.33, with a high forecast of GBX 5,500 and a low forecast of GBX 4,760. The average price target represents a 5.45% upside from the last price of GBX 4,982.

This chart shows the closing price for GNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Genus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/22/2021Peel HuntReiterated RatingBuyGBX 5,500
6/22/2021Peel HuntReiterated RatingBuyGBX 5,500
1/18/2021Liberum CapitalBoost Price TargetBuyGBX 4,490 ➝ GBX 4,760
6/30/2020Peel HuntReiterated RatingHold
6/18/2020Liberum CapitalBoost Price TargetBuyGBX 3,450 ➝ GBX 4,120
6/3/2020Peel HuntReiterated RatingHold
5/8/2020Peel HuntReiterated RatingHold
4/30/2020Peel HuntDowngradeHold
4/7/2020Peel HuntReiterated RatingBuy
4/1/2020HSBCBoost Price TargetBuyGBX 3,260 ➝ GBX 3,550
4/1/2020Peel HuntReiterated RatingBuy
3/23/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/27/2020Liberum CapitalReiterated RatingBuy
2/24/2020Peel HuntReiterated RatingBuy
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/6/2020Peel HuntReiterated RatingBuy
12/11/2019Peel HuntReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/28/2019Liberum CapitalBoost Price TargetBuyGBX 2,800 ➝ GBX 3,450
11/20/2019Peel HuntReiterated RatingBuy
11/20/2019Liberum CapitalReiterated RatingBuy
11/15/2019Jefferies Financial GroupInitiated CoverageHoldGBX 3,272
11/14/2019Peel HuntReiterated RatingBuyGBX 3,200
11/14/2019Liberum CapitalReiterated RatingBuyGBX 2,800
11/13/2019HSBCBoost Price TargetBuyGBX 3,000 ➝ GBX 3,260
11/11/2019Peel HuntReiterated RatingBuyGBX 3,200
11/4/2019Peel HuntReiterated RatingBuy
10/21/2019Peel HuntReiterated RatingBuy
10/21/2019Liberum CapitalReiterated RatingBuy
10/7/2019Peel HuntReiterated RatingBuy
9/16/2019Peel HuntReiterated RatingBuy
9/11/2019Peel HuntReiterated RatingBuyGBX 3,200
9/10/2019Peel HuntReiterated RatingBuyGBX 3,200
9/6/2019Liberum CapitalReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/22/2019Peel HuntReiterated RatingBuyGBX 3,200
8/22/2019Peel HuntReiterated RatingBuyGBX 3,200
8/1/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
5/29/2019Stifel NicolausInitiated CoverageHoldGBX 2,685
5/28/2019Peel HuntReiterated RatingBuy
5/17/2019Liberum CapitalReiterated RatingBuy
5/16/2019Peel HuntBoost Price TargetBuyGBX 2,800 ➝ GBX 3,200
5/2/2019Peel HuntReiterated RatingBuy
4/12/2019Liberum CapitalReiterated RatingBuy
4/8/2019Peel HuntReiterated RatingBuy
4/2/2019Peel HuntReiterated RatingBuy
3/25/2019Liberum CapitalReiterated RatingBuy
3/25/2019Peel HuntReiterated RatingBuy
3/11/2019HSBCReiterated RatingBuyGBX 2,650 ➝ GBX 2,700
3/5/2019Liberum CapitalUpgradeBuyGBX 2,400 ➝ GBX 2,500
2/28/2019Liberum CapitalReiterated RatingHoldGBX 2,400
2/28/2019Peel HuntReiterated RatingBuy
2/12/2019HSBCInitiated CoverageBuyGBX 2,650
2/1/2019Peel HuntReiterated RatingBuy
1/3/2019Peel HuntReiterated RatingBuy
12/7/2018Liberum CapitalReiterated RatingHold
12/6/2018Kepler Capital MarketsUpgradeBuyGBX 2,475 ➝ GBX 2,630
12/6/2018Peel HuntReiterated RatingHold
11/15/2018Liberum CapitalReiterated RatingHold
11/15/2018Peel HuntReiterated RatingHold
11/1/2018Peel HuntReiterated RatingHold
10/12/2018Peel HuntDowngradeHold
10/2/2018Peel HuntReiterated RatingHold
9/13/2018Kepler Capital MarketsReiterated RatingHold
9/7/2018Kepler Capital MarketsBoost Price TargetHoldGBX 2,470 ➝ GBX 2,540
9/6/2018Liberum CapitalReiterated RatingHoldGBX 2,400
9/6/2018Peel HuntDowngradeHoldGBX 2,600
9/4/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/4/2018Kepler Capital MarketsBoost Price TargetHoldGBX 2,353 ➝ GBX 2,470
7/2/2018Peel HuntReiterated RatingBuy
6/27/2018Liberum CapitalReiterated RatingHold
6/21/2018Peel HuntReiterated RatingBuyGBX 2,600
6/5/2018Liberum CapitalReiterated RatingHold
5/30/2018Peel HuntReiterated RatingBuy
5/22/2018Liberum CapitalReiterated RatingHold
4/3/2018Peel HuntReiterated RatingBuyGBX 2,600
3/12/2018Liberum CapitalReiterated RatingHoldGBX 2,400
3/1/2018Berenberg BankReiterated RatingHoldGBX 1,800
2/28/2018Peel HuntReiterated RatingBuyGBX 2,600
2/26/2018Liberum CapitalReiterated RatingHoldGBX 2,400
2/12/2018Liberum CapitalReiterated RatingHoldGBX 2,100
2/1/2018Peel HuntReiterated RatingBuyGBX 2,600
1/29/2018Liberum CapitalReiterated RatingHoldGBX 2,100
1/15/2018Liberum CapitalReiterated RatingHoldGBX 2,100
11/16/2017N+1 SingerReiterated RatingBuy
11/16/2017Liberum CapitalReiterated RatingHoldGBX 2,100
11/15/2017Kepler Capital MarketsReiterated RatingHoldGBX 2,353
11/15/2017Peel HuntReiterated RatingBuyGBX 2,600
11/7/2017Kepler Capital MarketsInitiated CoverageHoldGBX 2,353
10/30/2017N+1 SingerUpgradeBuyGBX 1,844 ➝ GBX 2,485
10/30/2017Liberum CapitalReiterated RatingHoldGBX 2,100
10/9/2017Peel HuntReiterated RatingBuyGBX 2,600
10/9/2017Liberum CapitalReiterated RatingHoldGBX 2,100
9/19/2017Liberum CapitalReiterated RatingHoldGBX 2,100
9/13/2017Liberum CapitalDowngradeHoldGBX 1,950 ➝ GBX 2,100
9/7/2017Numis SecuritiesReiterated RatingHoldGBX 1,815
9/4/2017Liberum CapitalReiterated RatingBuyGBX 1,950
9/4/2017Peel HuntReiterated RatingBuyGBX 2,600
8/24/2017Liberum CapitalReiterated RatingBuyGBX 1,950
7/10/2017Liberum CapitalReiterated RatingBuy
7/3/2017Liberum CapitalReiterated RatingBuy
6/19/2017Liberum CapitalReiterated RatingBuy
6/12/2017Liberum CapitalReiterated RatingBuy
6/1/2017Liberum CapitalReiterated RatingBuy
6/1/2017Peel HuntReiterated RatingBuy
5/2/2017Liberum CapitalReiterated RatingBuy
4/4/2017Numis SecuritiesReiterated RatingHold
4/3/2017N+1 SingerReiterated RatingHold
4/3/2017Peel HuntReiterated RatingBuy
4/3/2017Liberum CapitalReiterated RatingBuy
3/23/2017Berenberg BankInitiated CoverageHold
3/2/2017Liberum CapitalUpgradeBuy
2/23/2017N+1 SingerReiterated RatingHold
2/23/2017Peel HuntReiterated RatingBuy
2/23/2017Liberum CapitalReiterated RatingHold
11/17/2016Peel HuntReiterated RatingBuy
10/31/2016Liberum CapitalReiterated RatingHold
10/3/2016Liberum CapitalReiterated RatingHold
9/26/2016Liberum CapitalReiterated RatingHold
9/20/2016N+1 SingerUpgradeHold
9/9/2016Liberum CapitalDowngradeHold
9/8/2016Peel HuntReiterated RatingBuy
9/5/2016Liberum CapitalReiterated RatingBuy
8/22/2016Liberum CapitalReiterated RatingBuy
8/15/2016Liberum CapitalReiterated RatingBuy
8/11/2016Peel HuntReiterated RatingBuy
7/27/2016Liberum CapitalReiterated RatingBuy
7/27/2016Peel HuntReiterated RatingBuy
6/24/2016Numis SecuritiesReiterated RatingHoldGBX 1,426
(Data available from 6/22/2016 forward)
Genus logo
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Read More

Today's Range

Now: GBX 4,982
Low: 4,878
High: 4,982

50 Day Range

MA: GBX 5,072.70
Low: 4,694
High: 5,350

52 Week Range

Now: GBX 4,982
Low: 3,289.44
High: 5,515

Volume

36,768 shs

Average Volume

98,571 shs

Market Capitalization

£3.25 billion

P/E Ratio

67.69

Dividend Yield

0.61%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Genus?

The following Wall Street sell-side analysts have issued reports on Genus in the last year: Liberum Capital, Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for GNS.

What is the current price target for Genus?

3 Wall Street analysts have set twelve-month price targets for Genus in the last year. Their average twelve-month price target is GBX 5,253.33, suggesting a possible upside of 5.4%. Peel Hunt has the highest price target set, predicting GNS will reach GBX 5,500 in the next twelve months. Liberum Capital has the lowest price target set, forecasting a price of GBX 4,760 for Genus in the next year.
View the latest price targets for GNS.

What is the current consensus analyst rating for Genus?

Genus currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNS will outperform the market and that investors should add to their positions of Genus.
View the latest ratings for GNS.

What other companies compete with Genus?

How do I contact Genus' investor relations team?

Genus' physical mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company's listed phone number is +44-1256-347100. The official website for Genus is www.genusplc.com.